Table 2.
Characteristics of Patients with AMI treated in VHA
| Mean age, mean ± SD, y | 76.9 ± 6.9 |
| Age, % | |
| 65-69 y | 16.9 |
| 70-79 y | 46.1 |
| 80-89 y | 34.1 |
| >90 y | 2.9 |
| Ethnicity, % | |
| Hispanic | 6.9 |
| African American | 9.4 |
| White | 57.8 |
| Other | 0.6 |
| Unknown | 25.3 |
| Distance from home to hospital in miles, mean ± SD | 39 ± 117 |
| Geographic region of medical center, % | |
| New England | 3.2 |
| Mid-Atlantic | 10.0 |
| Great Lakes | 10.6 |
| North Plants | 8.7 |
| South Atlantic (including Puerto Rico) | 28.3 |
| Mississippi | 7.7 |
| South Plains | 11.5 |
| Great Basin | 9.5 |
| Pacific | 10.6 |
| Medical history, % | |
| Myocardial infarction | 26.5 |
| Lipid disorder | 64.3 |
| Coronary angioplasty/PCI w/in 6 mos | 3.5 |
| Coronary artery bypass surgery | 23.8 |
| Heart failure | 37.7 |
| Diabetes mellitus | 63.4 |
| Renal disease | 18.6 |
| Cerebrovascular disease | 9.6 |
| Chronic obstructive pulmonary disease | 21.7 |
| Dementia | 16.3 |
| Cancer | 11.5 |
| Current smoking | 13.5 |
| Medications at the time of admission for AMI, % | |
| Aspirin | 49.8 |
| Beta-blocker | 57.3 |
| Angiotensin-converting enzyme inhibitor | 48.4 |
| Lipid-lowering drug | 54.9 |
| Insulin | 15.6 |
2004-2006 (n = 11,609)